Assenagon Asset Management’s Caribou Biosciences CRBU Stock Holding History

Assenagon Asset Management’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-26,592	Closed	-$137K	–	1433
2024 Q1	$137K	Sell	26,592 -2,231,947	-99%	-$13.8M	﹤0.01%	1338
2023 Q4	$12.9M	Sell	2,258,539 -390,043	-15%	-$1.93M	0.03%	389
2023 Q3	$12.7M	Buy	2,648,582 +1,886,484	+248%	+$11.7M	0.04%	333
2023 Q2	$3.24M	Sell	762,098 -80,927	-10%	-$364K	0.01%	606
2023 Q1	$4.48M	Sell	843,025 -11,713	-1%	-$73K	0.02%	603
2022 Q4	$5.37M	Buy	854,738 +55,247	+7%	+$492K	0.02%	522
2022 Q3	$8.44M	Sell	799,491 -310,438	-28%	-$2.89M	0.03%	380
2022 Q2	$6.03M	Buy	+1,109,929	New	+$8.48M	0.02%	487

Other funds holding CRBU

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

EWM

Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management's CRBU Position: Q2 2024 in Review

Assenagon Asset Management sold out of Caribou Biosciences (CRBU) in Q2 2024, closing a stake of 26,592 shares — an estimated $137K sold.

Assenagon Asset Management first reported a position in CRBU in Q2 2022 and held it in 8 quarters. The position peaked at $12.9M in Q4 2023. 140 funds tracked by Wall St. Rank hold CRBU as of Q2 2024.

Assenagon Asset Management reported no remaining Caribou Biosciences position as of Q2 2024 after selling out during the quarter.
Assenagon Asset Management sold 26,592 Caribou Biosciences shares in Q2 2024, an estimated $137K.
Assenagon Asset Management first reported a position in Caribou Biosciences in Q2 2022 and held it in 8 quarters.
Assenagon Asset Management's Caribou Biosciences position peaked at $12.9M in Q4 2023.
140 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2024.

Based on Assenagon Asset Management's 13F filing for Q2 2024, filed 18 Jul 2024.